Nuvation Bio Inc. Files 8-K on Operations
Ticker: NUVB · Form: 8-K · Filed: May 14, 2024 · CIK: 1811063
Sentiment: neutral
Topics: operations, financial-condition, corporate-update
TL;DR
Nuvation Bio filed an 8-K updating its operational and financial info. Offices in NY.
AI Summary
Nuvation Bio Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition. The filing indicates the company's principal executive offices are located at 1500 Broadway, Suite 1401, New York, NY 10036, with a phone number of (332) 208-6102. Nuvation Bio Inc. was formerly known as Panacea Acquisition Corp. until April 30, 2020.
Why It Matters
This 8-K filing provides an update on Nuvation Bio Inc.'s operational and financial status, which is crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting operational and financial information, not indicating any immediate significant risks.
Key Players & Entities
- Nuvation Bio Inc. (company) — Registrant
- Panacea Acquisition Corp. (company) — Former company name
- May 14, 2024 (date) — Date of report
- 1500 Broadway, Suite 1401 New York, NY 10036 (address) — Principal executive offices
- (332) 208-6102 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Nuvation Bio Inc.?
The primary purpose of this 8-K filing is to report on Nuvation Bio Inc.'s results of operations and financial condition.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 14, 2024.
What is the current address of Nuvation Bio Inc.'s principal executive offices?
Nuvation Bio Inc.'s principal executive offices are located at 1500 Broadway, Suite 1401, New York, NY 10036.
What was Nuvation Bio Inc.'s former company name?
Nuvation Bio Inc.'s former company name was Panacea Acquisition Corp.
On what date did the name change from Panacea Acquisition Corp. to Nuvation Bio Inc. occur?
The date of the name change from Panacea Acquisition Corp. to Nuvation Bio Inc. was April 30, 2020.
Filing Stats: 509 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-05-14 16:20:59
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value per share NUVB The New Yo
- $11.50 — of Common Stock at an exercise price of $11.50 per share NUVB.WS The New York Stoc
Filing Documents
- d693344d8k.htm (8-K) — 27KB
- d693344dex991.htm (EX-99.1) — 61KB
- g693344g0513233738685.jpg (GRAPHIC) — 4KB
- 0001193125-24-138263.txt ( ) — 257KB
- nuvb-20240514.xsd (EX-101.SCH) — 4KB
- nuvb-20240514_def.xml (EX-101.DEF) — 13KB
- nuvb-20240514_lab.xml (EX-101.LAB) — 22KB
- nuvb-20240514_pre.xml (EX-101.PRE) — 14KB
- d693344d8k_htm.xml (XML) — 6KB
FINANCIAL STATEMENTS AND EXHIBITS
FINANCIAL STATEMENTS AND EXHIBITS (d) Exhibits. Exhibit Number Description 99.1 Press Release of Nuvation Bio Inc. dated May 14, 2024. 104 Cover Page Interactive Data File (embedded within XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 14, 2024 NUVATION BIO INC. By: /s/ Moses Makunje Name: Moses Makunje Title: VP, Finance, Principal Financial and Accounting Officer 3